FC
IOVA icon

Finepoint Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Finepoint Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,545,589
Closed -$9.88M – 40
2022
Q4 		$9.88M Sell
1,545,589
-40,454
-3% -$316K 3.19% 18
2022
Q3 		$15.2M Buy
1,586,043
+625,843
+65% +$7.22M 5% 13
2022
Q2 		$10.6M Buy
+960,200
New +$12.6M 3.67% 16

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Finepoint Capital's IOVA Position: Q1 2023 in Review

Finepoint Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 1,545,589 shares — an estimated $9.88M sold.

Finepoint Capital first reported a position in IOVA in Q2 2022 and held it in 3 quarters. The position peaked at $15.2M in Q3 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Finepoint Capital reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Finepoint Capital sold 1,545,589 Iovance Biotherapeutics shares in Q1 2023, an estimated $9.88M.
  • Finepoint Capital first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 3 quarters.
  • Finepoint Capital's Iovance Biotherapeutics position peaked at $15.2M in Q3 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Finepoint Capital's 13F filing for Q1 2023, filed 12 May 2023.